Supernus Pharmaceuticals Current Ratio 2011-2019 | SUPN

Supernus Pharmaceuticals current ratio from 2011 to 2019. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Supernus Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2019-03-31 $0.42B $0.15B 2.77
2018-12-31 $0.49B $0.16B 3.06
2018-09-30 $0.39B $0.14B 2.82
2018-06-30 $0.29B $0.10B 2.74
2018-03-31 $0.58B $0.12B 4.90
2017-12-31 $0.23B $0.12B 1.86
2017-09-30 $0.19B $0.11B 1.82
2017-06-30 $0.17B $0.09B 1.94
2017-03-31 $0.15B $0.08B 1.83
2016-12-31 $0.15B $0.08B 1.88
2016-09-30 $0.14B $0.07B 1.93
2016-06-30 $0.11B $0.07B 1.69
2016-03-31 $0.09B $0.06B 1.69
2015-12-31 $0.11B $0.06B 1.86
2015-09-30 $0.10B $0.04B 2.35
2015-06-30 $0.11B $0.04B 2.89
2015-03-31 $0.10B $0.03B 3.69
2014-12-31 $0.11B $0.03B 3.87
2014-09-30 $0.10B $0.02B 4.65
2014-06-30 $0.07B $0.02B 3.75
2014-03-31 $0.08B $0.03B 2.95
2013-12-31 $0.10B $0.03B 3.68
2013-09-30 $0.10B $0.03B 4.10
2013-06-30 $0.11B $0.02B 6.90
2013-03-31 $0.08B $0.03B 2.83
2012-12-31 $0.09B $0.02B 3.98
2012-09-30 $0.06B $0.03B 2.56
2012-06-30 $0.08B $0.02B 3.56
2012-03-31 $0.04B $0.02B 1.93
2011-12-31 $0.05B $0.02B 2.63
2011-09-30 $0.00B $0.00B 0.00
2011-06-30 $0.00B $0.00B 0.00
2011-03-31 $0.00B $0.00B 0.00
2010-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.645B $0.409B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $37.999B 6.92
Mylan (MYL) United Kingdom $8.773B 3.83
Teva Pharmaceutical Industries (TEVA) Israel $8.379B 3.28
Bausch Health Cos (BHC) Canada $7.555B 5.16
Dr Reddy's Laboratories (RDY) India $6.155B 23.02
Amphastar Pharmaceuticals (AMPH) United States $0.933B 52.16
Voyager Therapeutics (VYGR) United States $0.893B 0.00
Homology Medicines (FIXX) United States $0.809B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.778B 1.16
Akorn (AKRX) United States $0.535B 0.00
CymaBay Therapeutics (CBAY) United States $0.431B 0.00
Assembly Biosciences (ASMB) United States $0.371B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.347B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.275B 0.00
Sol-Gel Technologies (SLGL) Israel $0.161B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.125B 0.00
Acasti Pharma (ACST) Canada $0.071B 0.00
Agile Therapeutics (AGRX) United States $0.058B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.054B 0.00
Teligent (TLGT) United States $0.030B 0.00
Evoke Pharma (EVOK) United States $0.015B 0.00
Aevi Genomic Medicine (GNMX) United States $0.011B 0.00